D&B Business Directory
U C B
Public limited company Parent
Overview
U C B
You see, UCB wants to be a world leader when it comes to treating ailments related to the immune and central nervous systems (CNS). The company manufacturers prescription drugs to treat Crohn's disease, epilepsy, and Parkinson's disease. UCB's top products include Cimzia for Crohn's disease,Vimpat to treat epilepsy, and Neupro for Parkinson's disease. The company also makes allergy blockbuster Zyrtec. UCB has operations in nearly 30 countries, ...
Read More
and markets its products through an internal sales force and through strategic relationships with other pharmaceutical companies. Marketing, manufacturing, and development partners include AstraZeneca and Novartis. Financière de Tubize owns a majority stake in UCB.
Read Less
Allée de la Recherche 60 1070, Bruxelles Belgium See other locations
+32-25599999
www.ucb.com
188
12,102
$6.26 billion
8.83% -7.58% $15,585
1925 1925
Euronext Brussels:UCB
Stay on top of your Business Credit File
Get full access to view your D&B business credit file now for just $39/month!
View D&B Scores & Ratings
Contacts
Get in Touch with 18 Principals*
A D&B Hoovers Subscription is your foot in the door to U C B contact information.
D&B Hoovers Logo

Dynamic search and list-building capabilities

Real-time trigger alerts

Comprehensive company profiles

Valuable research and technology reports

Financial Data
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of December 31, 2020 (12 month period) in USD
Annual Revenue
$6.26 billion USD
1 USD = 0.8546 EUR